Recognizing Metabolic Bone Disease of Prematurity: It's About Bodybuilding! (PS3A)

Tuesday, September 14, 2021

2:00 PM – 2:20 PM CDT

CE: .33

NCC Codes:
RNC-NIC: 2
NNP-BC: 2
RNC-LRN: 3
Pharmacology Credits: .05

Paper Presenter(s)

Valarie A. Artigas, DNP, APRN, NNP-BC

Assistant Clinical Professor
University of Connecticut, School of Nursing, Neonatal Nurse Practitioner Prgram
New Milford, Connecticut, United States

Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Slides

Co-Author(s)

Mary Whalen, DNP, APRN, NNP-BC

Associate Clinical Professor
University of Connecticut, School of Nursing, NNP Program
Storrs, Connecticut, United States

Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Participants should be aware of the following financial/non-financial relationships:

Valarie A. Artigas, DNP, APRN, NNP-BC: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Mary Whalen, DNP, APRN, NNP-BC: I do not have any relevant financial / non-financial relationships with any proprietary interests.

As technology advances in relation to improvement of maternal/fetal outcomes, neonatal intensive care units are caring for preterm infants that are at high risk for bone demineralization, poor nutritional outcomes with the lagging of head and somatic growth. A specific aim of this abstract is to educate the neonatal nurse regarding the importance of aligning MBD assessment in their day to day care routines as a therapeutic intervention for prevention/identification of MBD.

Learning Objectives:

At the conclusion of this presentation, the learner will be able to:

Identify preterm infants at risk for MBD.
Describe the pharmacodynamics of certain medications that promote bone demineralization.
List the clinical sequalae as it relates to untreated MBD.
Identify care strategies to prevent MBD in the preterm infant.